Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Overland Pharma Announces $117 Million China JV with Allogene Therapeutics

publication date: Dec 15, 2020

Overland Pharmaceuticals, a new Shanghai in-licensing company, announced its second drug partnership in two days: Overland will form a $117 million China JV with Allogene Therapeutics of South San Francisco to bring allogenic CAR-T drugs to China. The JV, Allogene Overland, will have greater China rights to four off-the-shelf CAR-T candidates targeting BCMA, CD70, FLT3 and DLL3. Yesterday, Overland announced a $50 million JV with Switzerland's ADC Therapeutics to develop four antibody drug conjugate drugs in China. More details....

Stock Symbol: (NSDQ: ALLO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021